Skip to main content
Clinical Trials/EUCTR2015-003662-87-DK
EUCTR2015-003662-87-DK
Active, not recruiting
Phase 1

Pseudomonas Aeruginosa - Inhalation treatment, biomarkers and quality of life - Pseudomonas, Tazocin or Colistin

Aarhus University Hospital, Department of Respiratory Medicine0 sitesSeptember 22, 2015

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Chronic pulmonary disease patients, except cystic fibrosis patients, with confirmed pulmonary infection by sputum sample positive for Pseudomonas Aeruginosa.
Sponsor
Aarhus University Hospital, Department of Respiratory Medicine
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 22, 2015
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Aarhus University Hospital, Department of Respiratory Medicine

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, the patient must meet all of the following criteria:
  • ·Signed informed consent to participate in the study in accordance with local
  • regulations
  • ·Diagnosed with a chronic pulmonary disease by lung functions test or CT
  • ·Diagnosed with one positive sputum sample with PA during the last year
  • ·Age 18 \- 85 years inclusive
  • ·Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study
  • procedures specified in the protocol.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • ·Prophylactic treatment with any other antibiotic
  • ·Allergy to tazocin, ciprofloxacin or colistimethate\-sodium
  • ·Patients who are pregnant or planning a pregnancy
  • ·Patients with any solid organ transplant
  • ·Patients with cystic fibrosis
  • ·Patients on assisted ventilation
  • ·Bronchiectasis as a consequence of cystic fibrosis or focal endobronchial
  • lesion or otherwise curable causes (e.g. foreign body aspiration)
  • ·Be considered terminally ill or listed for transplantation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Respiratory infections with Pseudomonas aeruginosa in children with Cystic Fibrosis; early surveillance and preventioPulmonary P. aeruginosa infection, cystic fibrosisNutritional, Metabolic, EndocrineCystic fibrosis
ISRCTN11604593niversity Medical Center Utrecht (UMCU) (The Netherlands)100
Recruiting
Not Applicable
Airway colonization with Pseudomonas aeruginosa in chronic obstructive pulmonary disease (COPD)/non-CF bronchiectasis - an observational and biomaterial studyJ44.9J47B96.5Chronic obstructive pulmonary disease, unspecifiedBronchiectasisPseudomonas (aeruginosa) as the cause of diseases classified to other chapters
DRKS00023975ungenClinic Grosshansdorf80
Active, not recruiting
Phase 1
Clinical study to assess two different Pseudomonas aeruginosa eradication protocols in patients with cystic ¿brosiscystic fibrosisMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2015-003881-96-ITAZIENDA OSPEDALIERO-UNIVERSITARIA MEYER112
Active, not recruiting
Not Applicable
Early antibiotic treatment in pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomised policentric study on two different protocols - #FFC17/2007MedDRA version: 9.1Level: SOCClassification code 10038738Cystic fibrosis
EUCTR2008-006502-42-ITAZIENDA OSPEDALIERA MEYER
Completed
Not Applicable
Detection of Pseudomonas Aeruginosa in the Airways of Patients With CFCystic Fibrosis
NCT01303068University of New Mexico12